TELESTA THERAPEUTICS INC T.TST

raised the bar.

[cheetio]

If fda request another trial...........puff.......puff....... Ipsen and Active Biotech had been trying to muscle in on an increasingly competitive market. Phase III testing of tasquinimod began four years ago and since then other medicines have reached the market, raising the bar. April 2015 Cancer drug flop sends Ipsen, Active Biotech shares skidding Read more at Reutershttps://www.reuters.com/article/2015/04/16/ipsen-active-biotech-cancer-idUSL5N0XD19G20150416#YvDXmYw6iomgc7xA.99

[Jaytrading]

https://us19.chatzy.com/84732164784678

[investderp]

Gee... I wonder why?  How's your reading comprehension?  Shares in French drugmaker Ipsen and its Swedish partner Active Biotech fell sharply on Thursday after the companies announced an experimental medicine had failed to extend lives for prostate cancer sufferers.

[cheetio]

hey murky.......don't come yer bun's because ispen's aboard......they ain't fussy On April 18, 2011 - Active Biotech and Ipsen entered into a broad partnership to co-develop and commercialize Active Biotechs investigational compound Tasquinimod. Under the terms of the agreement, Active Biotech granted Ipsen exclusive rights to commercialize tasquinimod worldwide, except for North

[cheetio]

see see......not fussy...Ipsen is paying Active Biotech 25 million (about $36 million) up front and potentially another 150 million (roughly $217 million) in clinical, regulatory, and commercial milestones as part of a broad partnership agreement to co-develop and commercialize the latters anti-angiogenic cancer candidate, tasquinimod (ABR-215050). https://www.genengnews.com/gen-news-highlights